Author: Infomedia

Q4 2016 Update – DBM Participates at BIO’s 2016 International Conference and BIO’s 2016 Investor Forum, Continues an Active Intern Program

In June 2016, DBM’s Dr. Erik Schwiebert and Dr. John Streiff, with support from our long-time consultant, Dr. Douglas Hay, traveled to San Francisco to participate in the annual BIO International Meeting. There, DBM met with over 40 companies within and outside the BIO Partnering Forum. The NIH NIDDK also nominated and supported DBM at the convention with an Exhibit Kiosk in the NIH Innovation Zone. DBM was humbled and grateful for this opportunity. DBM was also an active partner in the BioAlabama exhibit.

Additionally, DBM was nominated by the NIH NDDK to participate in the Annual 2016 Bio Investor forum. And, in October, DBM traveled to San Francisco, once again, to present the results from an in vivo study with lead compounds from its Metabolic R&D program. DBM’s presentation was well received and its presence made possible by an NIDDK administrative supplement to an active SBIR award for registration and travel funds. DBM’s Dr. Schwiebert declared that “DBM continues to be honored and grateful for the deep support from the NIDDK in our partnering and business development efforts.”

Over the past year, DBM has been host to productive and outstanding interns. UAB students Cherie Verbal, Ophelia Johnson, and Albert Nakayama performed active work for DBM part-time from January through August 2016. Albert is continuing work with DBM going forward for the next 6-9 months as nearly full-time employee at present. These outstanding student interns were part of a Master’s program in Biomedical Engineering at UAB focused on Design and Commercialization. DBM is assisting Cherie in finding employment in the Huntsville area, while DBM is supporting in part Ophelia’s time in London where she has a prestigious fellowship in biomedical engineering and commercialization. In addition to this, DBM hosted 9 UAB Ph.D. students in exposure and immersion experiences at DBM and has identified a handful of promising candidates to join us and/or allied companies that we are helping as new startups.

Continue Reading »

It is who we are – It is what we do

Since the ‘light bulb idea moment’ in 2006 and the pre-launch and launch periods in 2007, DiscoveryBioMed, Inc. (DBM, Inc.) has held the solid core principle of Humanized Drug Discovery, the use of intact, living human cells in culture as the biologically-relevant and disease-relevant cell platforms on which to perform meaningful small molecule discovery and critical hit-to-lead and lead compound profiling. This core principle holds for both our internal R&D programs and our contract research organization (CRO) services business.

Continue Reading »

DiscoveryBioMed, Inc. is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

DiscoveryBioMed, Inc. (DBM, Inc.), fueled by recent advances in its Respiratory Diseases R&D program, has discovered and is developing a novel class of small molecule monotherapy that affects both major drug targets in CF. Proper function of the two target proteins that serve as channels for ions (conduits or transporters) for salt and water across the ciliated membrane that lines the airways, the cystic fibrosis transmembrane conductance regulator or CFTR (the protein product of the CF gene, a chloride ion channel) and ENaC (the epithelial sodium ion channel), becomes very abnormal in this devastating disease of children and young adults.

Continue Reading »

DiscoveryBioMed, Inc. is awarded a new Phase 2 SBIR grant award to develop new medicines to fight the diabetes and obesity epidemic in the US and globally

DiscoveryBioMed, Inc. (DBM, Inc.) has learned in recent days that it has been awarded a $1.61M Phase 2 Small Business Innovation Research (SBIR) grant award from the National Institutes of Health and its National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) to develop novel ‘first in class’ small molecule drugs to fight multiple disease abnormalities caused by high blood sugar (hyperglycemia) and high blood fat such as metabolic syndrome, type 2 diabetes mellitus and obesity.

Continue Reading »